Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1568-5608
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis ; volume:29 ; number:5 ; day:18 ; month:8 ; year:2021 ; pages:1371-1378 ; date:10.2021
Inflammopharmacology ; 29, Heft 5 (18.8.2021), 1371-1378, 10.2021
- Creator
-
Li, Mingwu
Zhou, Xianjie
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10787-021-00854-3
- URN
-
urn:nbn:de:101:1-2021122722345741841388
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Li, Mingwu
- Zhou, Xianjie
- SpringerLink (Online service)
Other Objects (12)
Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab
Distal esophageal involvement in Crohn disease: short treatment with adalimumab
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
Surgical treatment of ankylosing spondylitis deformity
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Presupposition processing declines with age
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases : a study of treatment trajectories on a patient level in routine care
Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab
Distal esophageal involvement in Crohn disease: short treatment with adalimumab
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
Surgical treatment of ankylosing spondylitis deformity
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Presupposition processing declines with age
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases : a study of treatment trajectories on a patient level in routine care
Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab
Distal esophageal involvement in Crohn disease: short treatment with adalimumab
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement
Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
Surgical treatment of ankylosing spondylitis deformity
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Presupposition processing declines with age
Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis